| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
3 companies
Scott M Rocklage last filed a Form 4 in June 2020, as Director at PULM. The filings on record cover 3 companies. Scott M Rocklage's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 168,873 shares of PULM. Net of sales, the PULM filings show accumulation of 38,805 shares.
Scott M Rocklage has 13 Form 4 filings on record from April 2015 to June 2020, across 3 companies: Aprea Therapeutics (APRE), 2019–2020; Director at CDTX, 2015–2018; Director at Pulmatrix (PULM), 2015–2016.
The 26 reported transactions were 10 option or other derivative awards, 6 open-market sales, 6 conversions and 2 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $267K and 3 sales worth about $20.0M.
The only open-market purchase was 38,805 shares of PULM at an average $6.88 on June 16, 2015, about $267K.
The largest open-market sale was 255,000 shares of APRE at an average $35.15 on May 19, 2020, about $9.0M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2020 | APRE Aprea Therapeutics, Inc. | Director, 10% Owner | Sell | 120,164 | $33.30 | $4,001,461.20 | -61.3% | |
| Jun 11, 2020 | APRE Aprea Therapeutics, Inc. | Director, 10% Owner | Sell | 245,000 | $28.75 | $7,044,411.50 | -75.2% | |
| May 19, 2020 | APRE Aprea Therapeutics, Inc. | Director | Sell | 255,000 | $35.15 | $8,963,250.00 | -73.8% | |
| Jun 16, 2015 | PULM Pulmatrix, Inc. | Director | Buy | 38,805 | $6.88 | $266,784.38 | +29.8% |